Trygg Pharma acquires factory in the UK (16.06.11)
See attached press release from Trygg Pharma. Trygg Pharma acquires a manufacturing facility from Lundbeck Pharmaceuticals Ltd. for DKK 120 million. The site is located in Seal Sands, Middlesbrough, UK.
The purchase of the facility in the UK is a step to increase the company’s manufacturing capacity further after the acquisition of EPAX AS from Austevoll Seafood ASA in November 2010.
The transaction is expected to close July 1st 2011, subject to remaining due diligence.
Aker BioMarine owns 50 % of Trygg Pharma Holding AS, which is a 50/50 joint venture with Lindsay Goldberg. To finance the transaction, Trygg Pharma Holding will complete a share issue to raise NOK 150 million in new equity, of which NOK 75 million will be contributed by Aker BioMarine.
The NOK 75 million contribution by Aker BioMarine will be financed with available cash and overdraft facility as well as payment of milestone number 2 of NOK 25 million from Lindsay Goldberg to Aker BioMarine end of June. The milestone payment is part of the deferred settlement of up to NOK 140 million from Lindsay Goldberg’s purchase of 50 % in Trygg Pharma Holding AS from Aker BioMarine AS (see stock exchange notice of Sept 3 2010).
For further information, please contact:
Re. Trygg Pharma: Terje Bakken, CEO Trygg Pharma, +47 906 54 227
Re. Aker BioMarine: Fredrik Nygaard, CFO & IR responsible, +47 24 13 00 00
The transaction is expected to close July 1st 2011, subject to remaining due diligence.
Aker BioMarine owns 50 % of Trygg Pharma Holding AS, which is a 50/50 joint venture with Lindsay Goldberg. To finance the transaction, Trygg Pharma Holding will complete a share issue to raise NOK 150 million in new equity, of which NOK 75 million will be contributed by Aker BioMarine.
The NOK 75 million contribution by Aker BioMarine will be financed with available cash and overdraft facility as well as payment of milestone number 2 of NOK 25 million from Lindsay Goldberg to Aker BioMarine end of June. The milestone payment is part of the deferred settlement of up to NOK 140 million from Lindsay Goldberg’s purchase of 50 % in Trygg Pharma Holding AS from Aker BioMarine AS (see stock exchange notice of Sept 3 2010).
For further information, please contact:
Re. Trygg Pharma: Terje Bakken, CEO Trygg Pharma, +47 906 54 227
Re. Aker BioMarine: Fredrik Nygaard, CFO & IR responsible, +47 24 13 00 00
Superba Krill
Norsk forbrukerkontakt:
Telefon: 815 56 333
Send epost
For international
Superba Krill enquiries:
For Europe:
Phone: +47 24 13 00 00
Send email
For North America:
Phone: 1-206-855-6736
Send email
Norsk forbrukerkontakt:
Telefon: 815 56 333
Send epost
For international
Superba Krill enquiries:
For Europe:
Phone: +47 24 13 00 00
Send email
For North America:
Phone: 1-206-855-6736
Send email
Aker BioMarine AS, Fjordalleen 16, P.o.Box 1423 Vika, 0115 Oslo, Norway, Phone: +47 24 13 00 00 - Fax: +47 24 13 01 10